Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

Plaque Reduction in the Selective HDL Delipidation Human Clinical Trial and ApoA-I Milano Trial were Similar Variable (mean ± SD) HDL Delipidation Therapy Trial* n = 14 Change in Total Atheroma Volume (mm 3 ) -12.18 ± Change in Percent Atheroma Volume - Plaque Burden -1.0% ± Change in Most Diseased 10 mm Segment Atheroma Volume (mm 3 ) *Waksman R, et al. J Am Coll Card. 2010;55:2727-2735 -6.24 ± ApoA-I Milano Trial n = 36 36.75 -14.10 ± 4.0% -1.1% ± 17.94 -7.20 ± 39.50 3.2% 12.60 Nissen S,et al. JAMA 2003;290:2292-2300.
The Reduction in Plaque was Greater in the HDL Selective Delipidation Human Trial Than the Results Obtained with Atorvastatin in the REVERSAL Trial Variable (mean ± SD) Change in Total Atheroma Volume (mm 3 ) -12.18 ± Change in Percent Atheroma Volume - Burden Plaque Change in Most Diseased 10 mm Segment Atheroma Volume (mm 3 ) + P
Page 1 and 2: Treating Lipid Abnormalities Beyond
Page 3 and 4: THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7 and 8: Lipoprotein Metabolism in Patients
Page 9 and 10: LOW HDL-C AS A RESIDUAL RISK FACTOR
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31 and 32: HDL Targeted Therapies: Niacin 1. D
Page 33 and 34: HATS: Angiographic and Clinical End
Page 35 and 36: � � Aim High randomized 3414 pa
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43: Preβ-HDL Enriched Plasma Obtained
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53 and 54: CETP Inhibitors CETP Torcetrapib Da
Page 55 and 56: The dal-HEART Program: Dalcetrapib
Page 57 and 58: LDL (mg/dL) Define Trial: Effect of
Page 59: FUTURE THERAPY FOR CARDIOVASCULAR D

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?